Liang, Xiaodong |
| Recruiting | 3 | 315 | RoW | TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Stage III Non-small-cell Lung Cancer | 12/22 | 03/25 | | |
Qin, Zhiquan |
NCT05622890: A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer |
|
|
| Recruiting | 3 | 35 | RoW | Mirvetuximab Soravtansine, IMGN853, MIRV | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer | 04/23 | 12/23 | | |
G-HOPE-001, NCT06238843: A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma |
|
|
| Enrolling by invitation | 3 | 450 | RoW | irinotecan, IBI343, paclitaxel | Innovent Biologics (Suzhou) Co. Ltd. | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | 12/26 | 12/27 | | |
NOVA-II, NCT04088318: A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients |
|
|
| Active, not recruiting | 2 | 170 | US, RoW | OQL011, Vehicle Ointment | OnQuality Pharmaceuticals (USA) LLC | Hand-Foot Skin Reaction (HFSR) | 02/24 | 06/24 | | |
NCT05555901: The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 116 | RoW | Fruquintinib+ chemotherapy, Bevacizumab+ chemotherapy | Fudan University | Metastatic Colorectal Cancer | 09/25 | 09/25 | | |
| Recruiting | 1/2 | 380 | RoW | PM8002 | Biotheus Inc. | Malignant Neoplasm | 11/25 | 11/25 | | |
NCT05914376: Safety of Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Tumors |
|
|
| Recruiting | 1 | 24 | RoW | Recombinant human IL-21-expressing oncolytic vaccinia virus injection, hV01 | Hangzhou Converd Co., Ltd. | Advanced Solid Tumors | 03/25 | 11/25 | | |